Publikationen

MelaGenix – Literaturauswahl
Patent USA (US2012108447): Brunner, G. and J. Atzpodien. 2015. Methods of predicting clinical outcome in malignant melanoma.
Brunner, G., A. Heinecke, L. Suter, N. Blödorn-Schlicht, H.-J. Schulze, and J. Atzpodien. 2014. Independent validation of a prognostic gene-signature based risk score in formalin-fixed paraffinembedded melanomas. Cancer Res. 74, Suppl. 19:2861.
Patent Australien (AU2009349220): Brunner, G. and J. Atzpodien. 2014. Methods of predicting clinical
outcome in malignant melanoma.
Patent Europa (EP2449376): Brunner, G. and J. Atzpodien. 2014. Methods of predicting clinical outcome in malignant melanoma.
Brunner, G., M. Reitz, A. Heinecke, A. Lippold, C. Berking, L. Suter, and J. Atzpodien. 2013. A ninegene signature predicting clinical outcome in cutaneous melanoma. J. Cancer Res. Clin. Oncol.
139:249-258.
Brunner, G., L. Suter, H.-J. Schulze, C. Berking, A. Heinecke, and J. Atzpodien. 2011. Validation of a
fresh-tissue based prognostic gene signature in formalin-fixed paraffin-embedded melanomas. Cancer
Res. 71, Suppl. 8:5070.
Brunner, G. und J. Atzpodien. Innovationspreis 2011 der BioRegionen in Deutschland.
Brunner, G., A. Heinecke, M. Reitz, A. Lippold, C. Berking, L. Suter, and J. Atzpodien. 2011. Identification and validation of a novel nine-gene signature predicting clinical outcome in malignant melanoma.
Cancer Res. 70, Suppl. 8:4652
Brunner, G. 2010. Der genetische Fingerabdruck des malignen Melanoms. Wirtschaftsmagazin für
den Hautarzt, 5-6:22-23.
Brunner, G., M. Reitz, A. Heinecke, A. Lippold, C. Berking, L. Suter, and J. Atzpodien. 2009. A novel
highly prognostic nine-gene signature can change the algorithm of adjuvant alfa-interferon in malignant melanoma at 1st diagnosis. Eur. J. Cancer Suppl. 7(3):14.
Hallermann, C., J. Atzpodien, M. Klein, A. Krause-Bergmann, G. Brodner, G. Strittmatter, G. Brunner,
H.-J. Schulze. 2009. Malignes Melanom – Update zu Diagnostik, Behandlung, Psychoonkologie und
Palliativmedizin. best practice onkologie, 6:4-22.
Brunner, G., M. Reitz, V. Schwipper, H. Tilkorn, A. Lippold, B. Biess, L. Suter, and J. Atzpodien. 2008.
Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in
malignant melanoma patients. Cancer Biother. Radiopharm., 23:451-459.
NeraCare GmbH
Siemensstr. 42  59199 Bönen
Tel.: +49 (2383) 919280  Fax: +49 (2383) 919281
www.neracare.de
Bethmann Bank
IBAN DE03501203830012282638
BIC DELBDE33
Ust.-ID DE299502450
Geschäftsführer:
Dr. Matthias Ackermann
Dr. Georg Brunner
Hamm HRB 8466

Download Report